Gaviscon mint chewable pills №48

Composition

Mechanism of action

Pharmacological action - antacid

Pharmacodynamics

When administered the active substances of the drug Gaviscon^® react quickly with acidic stomach contents. This forms alginate gel with a pH value close to neutral. The gel forms a protective barrier on the surface of the stomach contents, preventing the emergence of gastroesophageal reflux for up to 4 hours. In severe cases of reflux (regurgitation), the gel enters the esophagus, ahead of the rest of the gastric contents, where it reduces irritation of the esophageal mucosa.

Reduction of irritation of the mucous membrane of the esophagus is felt in 3-4 minutes after ingestion.

Pharmacokinetics

The drug does not have systemic bioavailability (not absorbed).

Gaviscon drug indications

Treatment of gastroesophageal reflux symptoms, such as sour belching, heartburn, dyspepsia (indigestion, feeling of heaviness in the stomach) that occur after eating,in patients with gastroesophageal reflux or during pregnancy.

Contraindications

Hypersensitivity to any of the components of the drug;

-phenylketonuria (see "Special instructions");

- children's age up to 12 years.

Carefully: in the presence of the following diseases or conditions, you should consult a doctor before using the drug: hypercalcemia, nephrocalcinosis and urolithiasis with the formation of calcium-oxalate stones, congestive heart failure, renal dysfunction.

Use during pregnancy and lactation

Clinical studies involving more than 500 pregnant women and the amount of data obtained in the post-registration period did not show congenital, feto-and neonatal toxicity of active substances.

Gaviscon^® can be used during pregnancy with clinical need and after consultation with a doctor.

Gaviscon^® can be used during breastfeeding.

Side effects

The frequency of adverse reactions was estimated based on the following criteria: very often (≥1 / 10); often (≥1 / 100, <1/10); infrequently (≥1 / 1000, <1/100); rarely (≥1 / 10000, <1/1000); very rarely (<1/10000) and an unspecified frequency (the frequency cannot be calculated from the available data).

On the part of the immune system: Unknown frequency - anaphylactic and anaphylactoid reactions, hypersensitivity reactions (urticaria).

On the part of the respiratory system, organs of the chest and mediastinum: unspecified frequency - respiratory effects (bronchospasm).

If any of the side effects indicated in the description are exacerbated or the patient has noticed other side effects that are not listed in the description, you should inform your doctor.

Interaction

Since Calcium carbonate, which is part of the drug, exhibits antacid activity, then between taking the drug Gaviscon^® and other drugs should take at least 2 hours, especially when taken simultaneously with blockers H₂- histamine receptors, antibiotics from the Tetracycline group, Digoxin, fluoroquinolone, iron salts, Ketoconazole. neuroleptics, levothyroxine sodium, thyroid hormones, penicillamine, beta-blockers (atenolol, Metoprolol, propranolol), corticosteroids, chloroquine, bisphosphonates and estramustine. See also “Special Instructions”.

Dosage and administration

Inside after thorough chewing.

Adults and children over 12 years old - 2-4 tab. after meals and before bedtime (up to 4 times per day).

If the symptoms persist after 7 days of taking the drug, you should consult a doctor to review the therapy.

Special patient groups

Elderly age. Dose change is not required.

Liver dysfunction. Dose change is not required.

Renal dysfunction. Take it with caution when you need to follow a diet with a very limited salt content (see "Special Instructions").

Overdosage

Symptoms: bloating is possible.

Treatment: symptomatic.

Special notes

Sodium. The drug contains sodium. In a dose of 4 table. the sodium content is 246 mg. This should be considered when it is necessary to follow a diet with a limited salt content, for example, in some cases of congestive heart failure and in cases of impaired renal function.

Calcium. Each dose of 4 table. contains 320 mg of calcium carbonate. Care must be taken when treating patients with hypercalcemia, nephrocalcinosis and urolithiasis with the formation of calcium-oxalate stones.

Aspartame. The drug contains aspartame, so it should not be used in patients with phenylketonuria. In addition, aspartame is a nonspecific sweetener, so patients with diabetes can use this drug.

Influence on ability to steer vehicles, mechanisms. The drug does not affect the ability to drive vehicles and mechanisms, as well as the classes of other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Storage conditions of the drug Gaviscon^®

At a temperature not higher than 30 ° C.

Keep out of the reach of children.